Acorn Capital Advisors
Latest statistics and disclosures from Acorn Capital Advisors's latest quarterly 13F-HR filing:
- Top 5 stock holdings are TERN, CGON, URGN, TRVI, PBYI, and represent 68.74% of Acorn Capital Advisors's stock portfolio.
- Added to shares of these 5 stocks: HELP (+$6.9M), VSTM (+$5.3M), URGN, Athira Pharma, JSPR.
- Started 1 new stock position in Athira Pharma.
- Reduced shares in these 3 stocks: TERN (-$9.1M), QTTB, VYNE.
- Acorn Capital Advisors was a net buyer of stock by $11M.
- Acorn Capital Advisors has $295M in assets under management (AUM), dropping by 49.82%.
- Central Index Key (CIK): 0002054410
Tip: Access up to 7 years of quarterly data
Positions held by Acorn Capital Advisors consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Acorn Capital Advisors
Acorn Capital Advisors holds 21 positions in its portfolio as reported in the December 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Terns Pharmaceuticals (TERN) | 23.9 | $71M | -11% | 1.7M | 40.40 |
|
| Cg Oncology (CGON) | 15.9 | $47M | 1.1M | 41.52 |
|
|
| Urogen Pharma (URGN) | 11.5 | $34M | +14% | 1.4M | 23.42 |
|
| Trevi Therapeutics (TRVI) | 9.1 | $27M | 2.1M | 12.52 |
|
|
| Puma Biotechnology (PBYI) | 8.3 | $25M | 4.1M | 5.95 |
|
|
| Candel Therapeutics (CADL) | 4.9 | $15M | 2.6M | 5.65 |
|
|
| Cybin Com New (HELP) | 4.4 | $13M | +114% | 1.6M | 8.18 |
|
| Verastem (VSTM) | 3.8 | $11M | +88% | 1.5M | 7.72 |
|
| Bicara Therapeutics (BCAX) | 3.7 | $11M | 643k | 16.83 |
|
|
| Protara Therapeutics Com Stk (TARA) | 3.2 | $9.3M | 1.8M | 5.33 |
|
|
| Onkure Therapeutics Class A Com (OKUR) | 2.8 | $8.2M | 2.8M | 2.90 |
|
|
| Cardiff Oncology (CRDF) | 1.9 | $5.5M | 2.0M | 2.81 |
|
|
| Athira Pharma Common Stock | 1.3 | $3.8M | NEW | 502k | 7.57 |
|
| Jasper Therapeuritc (JSPR) | 1.1 | $3.3M | +29% | 1.8M | 1.83 |
|
| Aura Biosciences (AURA) | 1.1 | $3.2M | 596k | 5.45 |
|
|
| Aadi Bioscience (WHWK) | 0.9 | $2.8M | 1.1M | 2.42 |
|
|
| Bioatla (BCAB) | 0.9 | $2.8M | 4.8M | 0.57 |
|
|
| Q32 Bio (QTTB) | 0.6 | $1.6M | -38% | 493k | 3.32 |
|
| X4 Pharmaceuticals | 0.4 | $1.1M | 273k | 4.00 |
|
|
| Acrivon Therapeutics Common Stock (ACRV) | 0.3 | $977k | 405k | 2.41 |
|
|
| Vyne Therapeutics (VYNE) | 0.0 | $827.070000 | -99% | 1.4k | 0.58 |
|
Past Filings by Acorn Capital Advisors
SEC 13F filings are viewable for Acorn Capital Advisors going back to 2024
- Acorn Capital Advisors 2025 Q4 filed Feb. 17, 2026
- Acorn Capital Advisors 2025 Q3 filed Nov. 17, 2025
- Acorn Capital Advisors 2025 Q2 filed Aug. 14, 2025
- Acorn Capital Advisors 2024 Q4 restated filed May 19, 2025
- Acorn Capital Advisors 2025 Q1 restated filed May 19, 2025
- Acorn Capital Advisors 2025 Q1 filed May 15, 2025
- Acorn Capital Advisors 2024 Q4 amended filed May 7, 2025